Relapsed/Refractory B Cell-Mediated Autoimmune Diseases

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsed/Refractory B Cell-Mediated Autoimmune Diseases trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingEarly Phase 1

NCT07322718

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cel…

China27 participantsStarted 2025-12-24

Treatment: RXIM002 product

RecruitingPhase 2

NCT07148791

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 year…

China9 participantsStarted 2025-09-05

Treatment: Anti-BCMA-CD19 CAR-T cells

All recent trials (3 shown)

Active — Not RecruitingPhase 1

NCT06294236

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subject…

United States7 participantsStarted 2024-04-29

Treatment: SC291